BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 28216194)

  • 1. Safety of resuming biologic DMARDs in patients who develop tuberculosis after anti-TNF treatment.
    Cho SK; Kim D; Won S; Han M; Lee J; Jang EJ; Kim TH; Bae SC; Sung YK
    Semin Arthritis Rheum; 2017 Aug; 47(1):102-107. PubMed ID: 28216194
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety of resuming tumour necrosis factor inhibitors in patients who developed tuberculosis as a complication of previous TNF inhibitors.
    Kim YJ; Kim YG; Shim TS; Koo BS; Hong S; Lee CK; Yoo B
    Rheumatology (Oxford); 2014 Aug; 53(8):1477-81. PubMed ID: 24681840
    [TBL] [Abstract][Full Text] [Related]  

  • 3. One-Year Tuberculosis Risk in Rheumatoid Arthritis Patients Starting Their First Tumor Necrosis Factor Inhibitor Therapy from 2008 to 2012 in Taiwan: A Nationwide Population-Based Cohort Study.
    Lim CH; Lin CH; Chen DY; Chen YM; Chao WC; Liao TL; Chen HH
    PLoS One; 2016; 11(11):e0166339. PubMed ID: 27832150
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of active tuberculosis in patients with inflammatory arthritis receiving TNF inhibitors: a look beyond the baseline tuberculosis screening protocol.
    Soare A; Gheorghiu AM; Aramă V; Bumbăcea D; Dobrotă R; Oneaţă R; Pintilie S; Milicescu M; Ancuţa I; Martin A; Sasu M; Ciofu C; Macovei L; Stoica V; Bojincă M; Mihai C
    Clin Rheumatol; 2018 Sep; 37(9):2391-2397. PubMed ID: 29150737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two-year persistence of golimumab as second-line biologic agent in rheumatoid arthritis as compared to other subcutaneous tumor necrosis factor inhibitors: real-life data from the LORHEN registry.
    Favalli EG; Sinigaglia L; Becciolini A; Grosso V; Gorla R; Bazzani C; Atzeni F; Sarzi Puttini PC; Fusaro E; Pellerito R; Caporali R
    Int J Rheum Dis; 2018 Feb; 21(2):422-430. PubMed ID: 29082659
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers.
    Seong SS; Choi CB; Woo JH; Bae KW; Joung CL; Uhm WS; Kim TH; Jun JB; Yoo DH; Lee JT; Bae SC
    J Rheumatol; 2007 Apr; 34(4):706-11. PubMed ID: 17309133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of tuberculosis in rheumatoid arthritis patients on tumour necrosis factor-alpha inhibitor treatment in Taiwan.
    Ke WM; Chen LS; Parng IM; Chen WW; On AW
    Int J Tuberc Lung Dis; 2013 Dec; 17(12):1590-5. PubMed ID: 24200274
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of tuberculosis, serious infection and lymphoma with disease-modifying biologic drugs in rheumatoid arthritis patients in Taiwan.
    Chiu YM; Lang HC; Lin HY; Yang MT; Fang CH; Yang YW; Schabert VF; Tang B
    Int J Rheum Dis; 2014 Dec; 17 Suppl 3():9-19. PubMed ID: 25496045
    [TBL] [Abstract][Full Text] [Related]  

  • 9. No increased risk of herpes zoster in TNF inhibitor and non-TNF inhibitor users with rheumatoid arthritis: epidemiological study using the Japanese health insurance database.
    Sakai R; Kasai S; Hirano F; Harada S; Kihara M; Yokoyama W; Tsutsumino M; Nagasaka K; Koike R; Yamanaka H; Miyasaka N; Harigai M
    Int J Rheum Dis; 2018 Sep; 21(9):1670-1677. PubMed ID: 29667330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative effectiveness of treatment options after conventional DMARDs failure in rheumatoid arthritis.
    Sung YK; Cho SK; Kim D; Choi CB; Won S; Bang SY; Cha HS; Choe JY; Chung WT; Hong SJ; Jun JB; Kim HA; Kim J; Kim SK; Kim TH; Lee HS; Lee J; Lee J; Lee SS; Lee SW; Lee YA; Nah SS; Suh CH; Yoo DH; Yoon BY; Bae SC;
    Rheumatol Int; 2017 Jun; 37(6):975-982. PubMed ID: 28132102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retrospective analysis to describe associations between tumor necrosis factor alpha inhibitors and COPD-related hospitalizations.
    Accortt NA; Chung JB; Bonafede M; Limone BL; Mannino DM
    Int J Chron Obstruct Pulmon Dis; 2017; 12():2085-2094. PubMed ID: 28790811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antirheumatic drugs and the risk of tuberculosis.
    Brassard P; Kezouh A; Suissa S
    Clin Infect Dis; 2006 Sep; 43(6):717-22. PubMed ID: 16912945
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Different Risk of Tuberculosis and Efficacy of Isoniazid Prophylaxis in Rheumatoid Arthritis Patients with Biologic Therapy: A Nationwide Retrospective Cohort Study in Taiwan.
    Liao TL; Lin CH; Chen YM; Chang CL; Chen HH; Chen DY
    PLoS One; 2016; 11(4):e0153217. PubMed ID: 27064275
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists.
    Carmona L; Gómez-Reino JJ; Rodríguez-Valverde V; Montero D; Pascual-Gómez E; Mola EM; Carreño L; Figueroa M;
    Arthritis Rheum; 2005 Jun; 52(6):1766-72. PubMed ID: 15934089
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents.
    Strangfeld A; Listing J; Herzer P; Liebhaber A; Rockwitz K; Richter C; Zink A
    JAMA; 2009 Feb; 301(7):737-44. PubMed ID: 19224750
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-viral opportunistic infections in new users of tumour necrosis factor inhibitor therapy: results of the SAfety Assessment of Biologic ThERapy (SABER) study.
    Baddley JW; Winthrop KL; Chen L; Liu L; Grijalva CG; Delzell E; Beukelman T; Patkar NM; Xie F; Saag KG; Herrinton LJ; Solomon DH; Lewis JD; Curtis JR
    Ann Rheum Dis; 2014 Nov; 73(11):1942-8. PubMed ID: 23852763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lack of adverse effect of anti-tumor necrosis factor-α biologics in treatment of rheumatoid arthritis: 5 years follow-up.
    Dewedar AM; Shalaby MA; Al-Homaid S; Mahfouz AM; Shams OA; Fathy A
    Int J Rheum Dis; 2012 Jun; 15(3):330-5. PubMed ID: 22709496
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of tuberculosis in patients with rheumatoid arthritis in Hong Kong--the role of TNF blockers in an area of high tuberculosis burden.
    Tam LS; Leung CC; Ying SK; Lee GK; Yim CW; Leung YY; Kun EW; Wong KK; Li EK
    Clin Exp Rheumatol; 2010; 28(5):679-85. PubMed ID: 20822708
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Are patients with rheumatoid arthritis still at an increased risk of tuberculosis and what is the role of biological treatments?
    Arkema EV; Jonsson J; Baecklund E; Bruchfeld J; Feltelius N; Askling J;
    Ann Rheum Dis; 2015 Jun; 74(6):1212-7. PubMed ID: 24608401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of Treatment Change Among Patients with Rheumatoid Arthritis Treated with TNF Inhibitors as First-Line Biologic Agent in the USA: A Cohort Study from Longitudinal Electronic Health Records.
    Jin Y; Landon JE; Krueger W; Liede A; Desai RJ; Kim SC
    BioDrugs; 2022 Jul; 36(4):521-535. PubMed ID: 35771381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.